Share
The National Agency for Food and Drug Administration and Control (NAFDAC) has said it has not received any application from Covid Vaccine manufacturer and therefore no vaccines have been approved by the Agency.
This was disclosed on Friday by the Director-General of the Agency, Prof. Mojisola Adeyeye at a virtual media briefing in Abuja.
Adeyeye said there are reports of fake vaccines in Nigeria, pleading with the public to beware as no COVID-19 vaccines have been approved by the Agency and fake vaccines can cause Covid-like illnesses or other serious diseases that could kill.
“Covid-19 vaccines are new, and the side effects or adverse events must be well monitored, therefore, if NAFDAC does not approve, the public should not use”. She added.
Coronavirus: NAFDAC declare say fake Covid- 19 vaccine don dey Nigeria
15 January 2021
Wia dis foto come from, Getty Images
Nigeria Agency wey dey regulate Food and Drug mata, NAFDAC don alert di public of di circulation of fake COVID-19 vaccines for di kontri.
Di Director General of di agency Prof. Mojisola Adeyeye wey raise di alarm say NAFDAC neva approve any Covid- 19 vaccine and warn say dis fake vaccines fit cause sickness wey relate to covid for pesin body or more serious sickness wey fit lead to death.
She explain say di agency neva receive application from any Covid- 19 vaccines manufacturer yet and since di vaccine dey new dem must monitor di side effects.
Attractive Market Opportunities in the Pharmacovigilance Market by 2020 marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.
AMCP Partnership Forum Develops Innovative Strategies to Support Biosimilar Use and Development
News provided by
Share this article
Share this article
ALEXANDRIA, Va., Dec. 21, 2020 /PRNewswire/ Managed care experts representing payers, pharmacists, integrated delivery systems, health economists and analysts, patient advocates, academicians, pharmaceutical manufacturers, and other key decision-makers convened for AMCP s Partnership Forum, Biosimilars: Policy, Practice, and Post-Marketing Surveillance to Support Treatment and Coverage Decisions, to identify actions that support biosimilar use and development. Biologics, including biosimilars, offer an opportunity to expand patient access to high-quality, cost-effective medications and reduce health care costs. Stakeholders from all corners of managed care pharmacy participated in AMCP s Partnership Forum and delivered innovative strategies to support biosimilar development and adoption. AMCP is dedicated t
Over 94 lakh patients have recovered from COVID-19 in India
India
Updated: Wednesday, December 16, 2020, 10:18 [IST]
New Delhi, Dec 16: More than 94 lakh patients have recovered from COVID-19 in the country, while presently there are re only about 3.4 lakhs active cases and it is declining further. More than 15.55 crore tests have been conducted till date, while cumulative positivity rate is 6.37% and the average daily positivity rate during last week was 3.00% in the country.
The recovery rate at 95.12% is amongst the highest in the world. India having 7178 cases per million population still figures among the lowest in the world. Even in terms of deaths which have occurred, India is amongst the lowest at 104 deaths per million population. In terms of case fatality rate also, India at 1.45% figures below the global average of 2.26%.